Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.58 |
| ▸ | GSK3B | P49841 | 4/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489020 | 0.94 | HDAC1 (0.56) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4498522 | 0.91 | HDAC1 (0.55) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4492020 | 0.90 | HDAC6 (0.62) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4486110 | 0.90 | HDAC1 (0.71) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4505755 | 0.89 | HDAC1 (0.68) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4476112 | 0.89 | HDAC1 (0.56) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4502352 | 0.86 | HDAC1 (0.70) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4494068 | 0.85 | HDAC1 (0.54) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4494476 | 0.84 | HDAC1 (0.65) | HDAC1HDAC2HDAC8GSK3BHDAC6 | |
| SCHEMBL4492977 | 0.83 | HDAC1 (0.65) | HDAC1HDAC2HDAC8GSK3BHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-20090030020-A1 | 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030020-A1 | 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors | MAP3K8, MAP4K2, MAP3K5 | HDAC1 1432/4885HDAC2 2544/4885HDAC8 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.